Delivery Order SPE2DB25D3012-SPE2DB25FXAMZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $14,389.20 to AmerisourceBergen Drug Corp for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL injectable pens. This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a continuation of the company's role as a critical pharmaceutical supplier to the federal government. The contract carries no set-aside designation, indicating it was competitively awarded...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.94 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 9, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order valued at $15,757.28 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. The contract, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a $21,626.20 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, with an ultimate completion date of September 2, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $19,218.06 to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This is a firm fixed-price, non-competitive set-aside delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,507.45 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed price, non-competitive delivery order is scheduled for completion by September 29, 2025, with performance at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework with the federal government. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,690.93 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 ml auto-injector pens. The contract was awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, and employs firm fixed price terms with no set-aside designation. Performance will take place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price contract was competitively awarded without set-asides and is scheduled for completion by June 20, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,791.56 for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens on August 11, 2025, with performance completion scheduled for August 12, 2025. This firm fixed price delivery order represents a non-set-aside, competitively awarded contract with no small business or other socioeconomic preferences applied. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXAMZDelivery Order
The Defense Logistics Agency awarded a $49,591.32 delivery order to AmerisourceBergen Drug Corp for the supply of Actemra Actpen (tocilizumab) 162 mg/0.9 mL auto-injector pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance to be completed by September 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's medical supply chain. This delivery order represents a task issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle, enabling the contractor to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. The delivery order for Actemra, a specialty pharmaceutical used in treating rheumatoid arthritis and other inflammatory conditions, exemplifies the company's role in providing both brand-name specialty medications and routine pharmaceutical supplies to Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $49.6k | 9/26/25 |